TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24490418

Group type: EXPERIMENTAL
Intervention: Health education + protective skill training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 21293249

Group type: COMPARATOR
Intervention: Losartan (n = 30)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Mizoribine (n = 35)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Combination of losartan and mizoribine (n = 34)
Number of subjects: 99
Study: 19878577

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) stage 3
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) stage 4
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) stage 5
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Individuals with CKD (stage 3-5)
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Hypertension as a cardiovascular risk factor
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Diabetes as a cardiovascular risk factor
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Geographical region (northeast vs central)
Number of subjects: 3117
Study: 16717306

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine 0.2 mg/kg
Number of subjects: 40
Study: 14687095

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 micro g.kg‐1
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Remifentanil 2.0 micro g.kg‐1
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Remifentanil 3.0 micro g.kg‐1
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (Propofol and Mivacurium 0.2 mg.kg‐1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Remifentanil 1.0 micro g.kg‐1 and Control
Number of subjects: 112
Study: 11352853

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg once daily for 28 days
Number of subjects: 92
Study: 9205820

Group type: EXPERIMENTAL
Intervention: Draflazine 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Draflazine 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Draflazine 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Draflazine 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Draflazine 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Draflazine 1 mg followed by 1 mg h‐1 infusion
Number of subjects: 0
Study: 8025138

Group type: EXPERIMENTAL
Intervention: Myocardial revascularization (surgical therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0
Study: 2821938

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16
Study: 29562405

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride 0.05 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 60
Study: 27600995

Group type: EXPERIMENTAL
Intervention: gemcitabine + erlotinib (G + E)
Number of subjects: 285

Group type: COMPARATOR
Intervention: gemcitabine + placebo (G + P)
Number of subjects: 285
Study: 26324753

Group type: EXPERIMENTAL
Intervention: Hands-on scanning with fetal pig simulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hands-on scanning with pregnant women
Number of subjects: 24
Study: 23425543

Group type: EXPERIMENTAL
Intervention: In-patient complete multivessel PCI
Number of subjects: 300

Group type: COMPARATOR
Intervention: Culprit (IRA)-only PCI
Number of subjects: 300
Study: 21274861

Group type: EXPERIMENTAL
Intervention: ITPA variants (rs1127354 and rs7270101)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: ITPase deficiency variable (combined ITPA variants)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: ITPase deficiency
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: ITPA variants
Number of subjects: 238
Study: 19097805

Group type: EXPERIMENTAL
Intervention: Outpatient bland embolization or chemoembolization
Number of subjects: 77
Study: 16510639

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 15241611

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Timolol 0.5% and Latanoprost 0.005%
Number of subjects: 61
Study: 11018852

Group type: EXPERIMENTAL
Intervention: zidovudine/didanosine/nevirapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: zidovudine/didanosine
Number of subjects: 0
Study: 7714940

Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated nets
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Untreated nets
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Untreated control villages
Number of subjects: 1700
Study: 2750573

Group type: EXPERIMENTAL
Intervention: Exercise-Meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Meal-Exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise Only
Number of subjects: 7

Group type: COMPARATOR
Intervention: Meal Only
Number of subjects: 7
Study: 1277437

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tartrazine
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) and Tartrazine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 140
Study: 31912523

Group type: EXPERIMENTAL
Intervention: Modified hydrophilic sandblasted and acid‐etched neck (mSLA; test)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Machined neck (M; control)
Number of subjects: 43
Study: 31521131

Group type: EXPERIMENTAL
Intervention: Theoretical lecture
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Theoretical lecture with training on anatomical models
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Theoretical lecture with training on cadavers
Number of subjects: 48
Study: 29025788

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention (8-week, 10-15 minutes, three times a week during hemodialysis)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 41
Study: 24652887

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 440
Study: 25302067

Group type: EXPERIMENTAL
Intervention: Tianjiu therapy for 1 year
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tianjiu therapy for 2 years
Number of subjects: 102
Study: 22750124

Group type: EXPERIMENTAL
Intervention: Attentional switching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response conflict
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity between dACC and inferior temporal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity between dACC and posterior parietal cortex
Number of subjects: 0
Study: 19640960

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3175

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3175
Study: 17208602

Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy (OIT)
Number of subjects: 7
Study: 15642674

Group type: EXPERIMENTAL
Intervention: Blood stem cell (BSC) allografts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow (BM) allografts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with extensive chronic GVHD
Number of subjects: 0
Study: 12092994

Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Excel (D17)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Manual brush with tartar control dentifrice
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 81
Study: 9820263

Group type: EXPERIMENTAL
Intervention: Yoga-based intervention consisting of 11 yoga postures, given twice weekly for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Wrist splint to supplement current treatment
Number of subjects: 42
Study: 8562352

Group type: COMPARATOR
Intervention: Four-drug chemotherapy regimen (ECMV: etoposide, cyclophosphamide, methotrexate, vincristine)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Two-drug chemotherapy regimen (EV: etoposide and vincristine)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Four-drug chemotherapy regimen (ECMV)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Two-drug chemotherapy regimen (EV)
Number of subjects: 310
Study: 2012514

Group type: EXPERIMENTAL
Intervention: Controlled-release Sinemet (levodopa/carbidopa)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Sinemet (levodopa/carbidopa)
Number of subjects: 10
Study: 6813484

Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) and Gold sodium thiomalate (GSTM)
Number of subjects: 52
Study: 30616671

Group type: EXPERIMENTAL
Intervention: Regional adipose tissue grafting (AT-G)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham procedure (SP)
Number of subjects: 38
Study: 28229508

Group type: EXPERIMENTAL
Intervention: 8-week meditation training based on mindfulness-based stress reduction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 25179761

Group type: EXPERIMENTAL
Intervention: SafeR (AAI‐DDD changeover mode)
Number of subjects: 650

Group type: COMPARATOR
Intervention: DDD (standard mode)
Number of subjects: 650
Study: 24637979

Group type: EXPERIMENTAL
Intervention: 300 UI BTX‐A
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 UI BTX‐A
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study: 21157386

Group type: EXPERIMENTAL
Intervention: Continuous cycle to fatigue at 75% peak power output (FAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30‐minute cycle alternating 1‐minute 60% and 1 minute 90% Wmax (60/90)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30‐minute cycle alternating 1‐minute 55% and 4‐minute 80% Wmax (55/80)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Squatting 8 sets of 10 repetitions at 10 repetition maximum (RESIST)
Number of subjects: 0
Study: 19472557

Group type: EXPERIMENTAL
Intervention: Desensitizing paste containing 8% arginine and calcium carbonate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nupro pumice prophylaxis paste
Number of subjects: 45
Study: 17550366

Group type: EXPERIMENTAL
Intervention: Telephone counseling (up to six sessions)
Number of subjects: 897

Group type: COMPARATOR
Intervention: Pamphlet on healthy lifestyles
Number of subjects: 897
Study: 14634808

Group type: EXPERIMENTAL
Intervention: Action effects with target-compatible color effects (e.g., blue word -> left key -> blue patch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without action effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group with target-incompatible action effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color words as action effects
Number of subjects: 0
Study: 11203779

Group type: EXPERIMENTAL
Intervention: 3‐Sited
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Directed‐Shrinkage
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resin‐Modified Glass‐Ionomer Cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flowable Composite
Number of subjects: 40
Study: 9972902

Group type: EXPERIMENTAL
Intervention: Cold blood intermittent cardioplegia (CBIC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm continuous blood cardioplegia (WCBC)
Number of subjects: 20
Study: 8527353

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 161

Group type: COMPARATOR
Intervention: Enalapril 10 mg once daily
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 161

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 161
Study: 2689045

Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1233072

Group type: EXPERIMENTAL
Intervention: Salbutamol (8 mg) administered twice daily as a sustained release formulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mug) administered by aerosol
Number of subjects: 24
Study: 31405750

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine rinse (10% solution, 2500 mg daily, 5 times daily during radiotherapy and 2 weeks post-radiotherapy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine rinse
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 32
Study: 27655375

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic Cholecystectomy (MLC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional Laparoscopic Cholecystectomy (CLC)
Number of subjects: 115
Study: 26314451

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tourniquet application
Number of subjects: 44
Study: 23222413

Group type: EXPERIMENTAL
Intervention: Ginger (2.0 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22016912

Group type: EXPERIMENTAL
Intervention: Microwave disinfection (once a week for 3 minutes at 650W)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Brushing with coconut soap and soft toothbrush (control group)
Number of subjects: 40
Study: 18449063

Group type: EXPERIMENTAL
Intervention: Levofloxacin (10 mg/kg twice daily)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (14:1; amoxicillin 45 mg/kg twice daily)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Levofloxacin and Amoxicillin/clavulanate
Number of subjects: 1650
Study: 17139433

Group type: EXPERIMENTAL
Intervention: Isothermic carbon dioxide at 37 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypothermic carbon dioxide at 21 degrees C
Number of subjects: 30
Study: 14503827

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (phosphate-buffered saline)
Number of subjects: 94
Study: 10866907

Group type: EXPERIMENTAL
Intervention: ondansetron 0.1 mg/kg IV injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo (normal saline) IV injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: diphenhydramine 30 mg IV injection
Number of subjects: 60
Study: 9358912

Group type: EXPERIMENTAL
Intervention: Daily administration of 25,000 IU vitamin A and 30 mg beta-carotene
Number of subjects: 18500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18500
Study: 8451310

Group type: COMPARATOR
Intervention: 560 ml of CMW
Number of subjects: 18

Group type: COMPARATOR
Intervention: 560 ml of APM-sweetened soft drink (340 mg APM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 280 ml of APM-sweetened mineral water (340 mg APM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 280 ml of carbonated mineral water (CMW)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 280 ml of CMW with 340 mg of encapsulated APM
Number of subjects: 18
Study: 2870944

Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate (PPT) 100 mg alternating with placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Flupenthixol decanoate (FPX) 40 mg
Number of subjects: 39
Study: 30833381

Group type: COMPARATOR
Intervention: Vitamin D
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Calcium plus Vitamin D
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Advanced or multiple adenomas
Number of subjects: 1121
Study: 30440907

Group type: EXPERIMENTAL
Intervention: RAPAEL Smart Board therapy (30 minutes a day, 5 days per week, for 4 weeks) in addition to traditional treatments (30 minutes of functional arm movement therapy)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Traditional treatment (two 30-minute sessions, 5 days per week, for 4 weeks)
Number of subjects: 17
Study: 26586610

Group type: EXPERIMENTAL
Intervention: Liquid LT4 at breakfast
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo before breakfast
Number of subjects: 77
Study: 25132122

Group type: EXPERIMENTAL
Intervention: HCB+nopal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HSPB+nopal
Number of subjects: 14
Study: 22806823

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21265123

Group type: EXPERIMENTAL
Intervention: Complex preventive therapy including wobenzym
Number of subjects: 0
Study: 17309376

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Breathing Retraining (BR)
Number of subjects: 10
Study: 16298720

Group type: EXPERIMENTAL
Intervention: AAV haplotype (intermediate PTC/PROP taste sensitivity)
Number of subjects: 567

Group type: COMPARATOR
Intervention: PAV haplotype (taster)
Number of subjects: 567

Group type: COMPARATOR
Intervention: AVI haplotype (nontaster)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Taste motivation measured by the Wisconsin Inventory of Smoking Dependence Motives‐68 taste/sensory processes scale
Number of subjects: 567
Study: 12212981

Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 14
Study: 9469682

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol (HDL) 5 mg plus lorazepam (LZ) 2 mg (9 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular lorazepam (LZ) 2 mg (11 patients)
Number of subjects: 20
Study: 7628515

Group type: EXPERIMENTAL
Intervention: Treadmill exercise with inflated cuffs around thighs
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treadmill exercise without inflated cuffs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cycle exercise using arms
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cycle exercise using legs
Number of subjects: 26
Study: 2744799

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31271891

Group type: EXPERIMENTAL
Intervention: Retromandibular transparotid approach (Group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Retromandibular anteroparotid approach (Group B)
Number of subjects: 26
Study: 28758796

Group type: EXPERIMENTAL
Intervention: Film on idiopathic environmental intolerance (IEI)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Film on the dangers of electromagnetic fields
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control film about cystic fibrosis
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 212
Study: 27117727

Group type: EXPERIMENTAL
Intervention: Movement-Pattern Training (MPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list (Control)
Number of subjects: 35
Study: 25616927

Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV-LOW) at 0.25 mg/kg/h
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV-PCI) at 1.75 mg/kg/h
Number of subjects: 2196

Group type: COMPARATOR
Intervention: Heparin ± GPI
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Patients with AST
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2196

Group type: EXPERIMENTAL
Intervention: BIV-LOW
Number of subjects: 2196
Study: 23505929

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg oral dose administered 4 hours before the match)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (administered to the control group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison between Allopurinol and Placebo
Number of subjects: 12
Study: 21382864

Group type: EXPERIMENTAL
Intervention: Snoezelen room sessions (30 minutes, twice a week for six weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Volunteer visits (control group)
Number of subjects: 24
Study: 19112801

Group type: EXPERIMENTAL
Intervention: Active gel (topical gel containing growth factors, cytokines, and soluble matrix proteins)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study: 16410447

Group type: EXPERIMENTAL
Intervention: PCT‐FFP
Number of subjects: 121

Group type: COMPARATOR
Intervention: C‐FFP
Number of subjects: 121
Study: 14653030

Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis using recombinant growth-factor protein application or growth factor gene therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiogenic therapy (specifics not provided).
Number of subjects: 0
Study: 11096046

Group type: EXPERIMENTAL
Intervention: Gadolinium (Gd-BOPTA dimeglumine), 0.2 mmol/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 32
Study: 9248314

Group type: EXPERIMENTAL
Intervention: Illustrated COOP charts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unillustrated COOP charts
Number of subjects: 0
Study: 8445223

Group type: EXPERIMENTAL
Intervention: Plugged-percutaneous biopsy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transjugular biopsy
Number of subjects: 100
Study: 3530634

Group type: EXPERIMENTAL
Intervention: Steel Ring
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: VCu200
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: TCu220c
Number of subjects: 600
Study: 28715800

Group type: EXPERIMENTAL
Intervention: Micronized Progesterone (MP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Depo Medroxyprogesterone 17‐acetate (MPA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dienogest (DIE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 27052661

Group type: EXPERIMENTAL
Intervention: Intuitive eating intervention
Number of subjects: 0